A recent publication in the Journal of Clinical Endocrinology and Metabolism provides new data about the role of growth hormone (GH) in bone in Prader–Willi syndrome. The lack of positive effects of long-term GH therapy on BMD in young adults with Prader–Willi syndrome highlights the need to improve the transition from adolescent to adult health care.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kroonen, L. T., Herman, M., Pizzutillo, P. D. & MacEwen, G. D. Prader–Willi syndrome: clinical concerns for the orthopaedic surgeon. J. Pediatr. Orthop. 26, 673–679 (2006).
Jørgensen, A. P. et al. Two years of growth hormone treatment in adults with Prader–Willi syndrome do not improve the low BMD. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2012-3378.
Cassidy, S. B., Schwartz, S., Miller, J. L. & Driscoll, D. J. Prader–Willi syndrome. Genet. Med. 14, 10–26 (2012).
van Nieuwpoort, I. C. et al. The GH/IGF-I axis and pituitary function and size in adults with Prader–Willi syndrome. Horm. Res. Paediatr. 75, 403–411 (2011).
Grugni, G. et al. Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader–Willi adults and obese controls. Clin. Endocrinol. (Oxf.) http://dx.doi.org/10.1111/cen.12142.
Coupaye, M. et al. Growth hormone therapy for children and adolescents with Prader–Willi syndrome is associated with improved body composition and metabolic status in adulthood. J. Clin. Endocrinol. Metab. 98, E328–E335 (2013).
de Lind van Wijngaarden, R. F. et al. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader–Willi syndrome: a randomized controlled trial. J. Clin. Endocrinol. Metab. 94, 3763–3771 (2009).
Edouard, T. et al. Muscle-bone characteristics in children with Prader–Willi syndrome. J. Clin. Endocrinol. Metab. 97, E275–E281 (2012).
Biver, E. et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 2703–2713 (2011).
Napoli, N. et al. Effect of ghrelin on bone mass density: the InChianti study. Bone 49, 257–263 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Grugni, G. Prader–Willi syndrome—GH therapy and bone. Nat Rev Endocrinol 9, 320–321 (2013). https://doi.org/10.1038/nrendo.2013.74
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.74
This article is cited by
-
Analysis of Circulating Mediators of Bone Remodeling in Prader–Willi Syndrome
Calcified Tissue International (2018)
